Faegre Baker Daniels LLP
600 East 96th Street, Suite 600
Indianapolis, Indiana 46240
Phone +1 317 569 9600
Fax +1 317 569 4800
October 12, 2017
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Re: Endocyte, Inc. Registration Statement on Form S-3 Filing
Ladies and Gentlemen:
Our client, Endocyte, Inc. (the “Company”), is filing a Registration Statement on Form S-3 for the registration under the Securities Act of 1933, as amended, with respect to: (a) for issue and sale by the Company from time to time of $150,000,000 of shares of common stock, shares of preferred stock, senior debt securities, subordinated debt securities, warrants, rights and units; and (b) for resale from time to time by certain stockholders of Company of up to: (i) 5,278,000 shares of common stock and (ii) 722,000 shares of common stock issuable upon the exercise of an outstanding warrant.
The Company also has pending two confidential treatment requests, one of which was originally submitted to the Securities and Exchange Commission (the “SEC”) on August 9, 2017 and has been subject to correspondence with the Staff of the SEC (CF #35409), and the other of which was submitted to the SEC on October 3, 2017.
Please feel free to call the undersigned at 317-569-4887 with respect to any matters relating the Registration Statement.
Very truly yours,
FAEGRE BAKER DANIELS LLP
/s/ Christine G. Long
Christine G. Long